Articles

Insights From the Experts at Teiko

Learn about the latest advances in immune profiling from Teiko’s team of scientific experts.

CLIA Validation Data for Teiko Bio’s PBMC Immune Profiling Assay

In this live webinar, Ramji Srinivasan, cofounder and CEO of Teiko Bio, will walk through the precision and stability data for our mass cytometry assay for pan-immune profiling of PBMCs isolated from healthy human clinical samples.

Read Article

Discovery of immune-related adverse event associations in metastatic melanoma

Ramji Srinivasan, cofounder and CEO of Teiko Bio, shares original research on blood-based biomarkers of immune-related adverse events in metastatic melanoma performed by Teiko scientists in collaboration with Dr. Siwen Hu-Lieskovan of Huntsman Cancer Institute.

Read Article

Understanding the immune setpoint – a new approach to cancer treatment

Matthew Spitzer, Associate Professor at UCSF and scientific cofounder of Teiko Bio, explains how understanding each patient’s individual “immune setpoint” could be the key to maximizing cancer treatment efficacy.

Read Article

Whole Blood or PBMCs for immune profiling?

Dr. Jolien Sweere discusses data from a technical validation experiment performed by Teiko Bio showing how mass cytometry immune profiling data from whole blood compares to data from PBMCs.

Read Article

White background with black and red text in the middle surrounded by squares of abstract red paint splotches. The title reads "Teiko.bio Peripheral immune Monitoring" and the subtitle reads "What looking beyond the tumor microenvironment taught us about immunotherapy."

What looking beyond the tumor microenvironment has taught us about immunotherapy

Dr. Jolien Sweere walks us through scientific publications showing that immune responses outside the tumor are necessary for effective immunotherapy.

Read Article

Abstract image covered with lots of circular cell-like shapes in pink, white, teal, dark blue, and red.

Accelerating therapeutic discovery in blood cancer

We highlight six recent key discoveries made using mass cytometry across a wide range of blood cancers including AML ALL, lymphoma, and myeloma.

Read Article

Immune responses to cancer immunotherapy outside the tumor

Where do T cells get activated after cancer immunotherapy? Matthew Spitzer, PhD, reviews current literature and his lab’s recent Cell publication in this educational webinar.

Read Article

Black icons of a hotdog and soda over an eggshell background with black text below and the words "0% inflation" in bright red on the top right corner. Text on the bottom reads "You can't use the Costco hot dog and soda deal to measure inflation. It's been $1.50 since 1985."

What the Costco hot dog teaches us about our immune system

What the Costco hotdog and soda deal and inflation can teach us about better understanding the immune system.

Read Article

Customer Spotlight: Shernan Holtan, MD

Dr. Shernan Holtan discusses her research into a pregnancy hormone that may hold the key to treating life-threatening graft-vs-host diseases and how Teiko helped her overcome the barriers to high-dimensional immune profiling.

Read Article

Two peas in a pod: The complementary capabilities of single-cell RNA seq and mass cytometry

Researchers have used scRNAseq and CyTOF as complementary tools in a wide variety of published studies to provide additional breadth, depth, and coverage when analyzing cellular processes. Here are a few specific examples that illustrate the diversity and range of these approaches in a variety of biomedical research settings.

Read Article

Illustration. In the center is a grey mass labeled "tumor" under a magnifying glass. Inside the tumor are three grey cells all with "zzz" above them. Outside the magnifying glass (and therefore outside the tumor) in the four corners are different depictions. Top left shows three red cells and is labeled "novel T cell clones". Top right shows a lymph node with red T cell zones and the words "LN trafficking required". Bottom right shows two red T cells in a blood vessel labeled "LAG-3 and CD8+" with the words "peripheral biomarkers". Bottom left shows a spleen with the same grey, sleeping T cells. There's a red lightning bolt and the words "impaired systemic immune response in cancer".

Peripheral blood analysis is key to developing effective cancer immunotherapies

Although most research focuses on tumor-killing immune cells at the site of the tumor, new research increasingly demonstrates the value of studying circulating immune cells in peripheral blood to identify new therapeutic targets to enhance tumor-killing immune responses. We highlight recent publications with peripheral blood biomarkers and discuss recommendations for how to incorporate peripheral blood immune profiling into your drug development pipeline.

Read Article

A ring of grey and black in the center split into 3 sections with the words Flow, Mass, Spectral going around it clockwise. A dashed line coming out from the ring separates the rest of the space into three sections. Surrounding the ring are six colored circles each with a white icon. The circles directly opposite each other are the same color, but different shades (red opposite pink, blue opposite light blue, green opposite light green). Red shows a pencil, pink shows a grid-like matrix, Blue shows four dials, light blue shows only two; green shows a heavy metal spectrum with distinct lines, light green shows fluorescence spectrum with overlap. The green circle is in the Mass segment, the red overlaps between Mass and Flow, the Blue overlaps between Mass and Spectral. The Mass segment is the only one without any light colored circles.

Flow vs. Spectral vs. Mass Cytometry: What’s the difference?

What’s the difference between flow, spectral, and mass cytometry? We highlight the differences between these three different cytometry platforms used by drug developers to characterize the immune system so you can determine which platform provides you the richest information to advance your research and therapeutic development.

Read Article

Five things to look for in an immune profiling partner

Make the most of your time and resources by choosing an immune profiling partner who can advance your oncology, autoimmune, or infectious disease pipelines. Here are five things to look for when evaluating an immune profiling partner.

Read Article